Dr. Klaus Breiner
Dr. Breiner is an investment advisor for BB BIOTECH VENTURES. He has invested in a broad range of life science companies. Before becoming a venture capitalist, he was a business consultant with Booz Allen & Hamilton in Zurich and a researcher at the Swiss Federal Institute of Technology (ETH) in Zurich and at the Center for Molecular Biology in Heidelberg (ZMBH). Dr. Breiner holds an MA in chemistry from the University of North Carolina, Chapel Hill, and a PhD in Molecular Biology from the University of Heidelberg. He has authored several scientific publications and has received prestigious academic awards and fellowships. Dr. Breiner’s past and present board assignments include Agendia BV, AM_Pharma BV, Alpex Pharma SA, Cadence Pharmaceuticals Inc, Glycart Biotechnology AG, Orthocon Inc, and Vaximm AG.